Shattuck Labs, Inc. (STTK)


Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK). The investigation concerns whether Shattuck and certain of its officers and/or directors have violated federal securities laws.

On November 9, 2021, Shattuck issued a press release reporting its financial results for the third quarter of 2021 and providing corporate updates.  Among other items, Shattuck reported that “[i]n November 2021, Shattuck and Takeda [Pharmaceutical Company Limited] mutually agreed to termination of the Collaboration Agreement for SL-279252 and SL-115154, originally executed in 2017.  Shattuck is no longer required to satisfy any remaining performance obligations, the Company will not make any payments to or receive any future milestone or royalty payments from Takeda, and all options to license and rights of first negotiation held by Takeda under the Collaboration Agreement were terminated.”  In addition, Shattuck reported the appointment of Dr. George Golumbeski as chairman of the Company’s Board of Directors, following the resignation of former chairman Josiah Hornblower in October 2021.  On this news, Shattuck’s stock price fell $5.45 per share, or 28.62%, to close at $13.59 per share on November 9, 2021.

If you are aware of any facts relating to this investigation, or purchased Shattuck shares, you can assist this investigation. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC: 212-697-6484. 

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.